Geron Corporation Common Stock GERN
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-12T02:10:48.099Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-12-18
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T23:23:13.370928865Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-12T02:10:47.258011+00:00
Geron Corporation Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 1.83 | 136.6% | 84.8% | |||
| 25Δ | 1.71 | 125.2% | 74.0% | |||
| 30Δ | 1.60 | 113.9% | 63.1% | |||
| 35Δ | 1.48 | 102.5% | 52.3% | |||
| 40Δ | 1.37 | 91.1% | 41.5% | |||
| 45Δ | 1.25 | 79.7% | 30.7% | 1.04 | 69.0% | 8.0% |
| 50Δ | 1.14 | 68.4% | 19.9% | 1.19 | 90.0% | 7.7% |
| 55Δ | 1.02 | 57.0% | 9.1% | 1.34 | 111.1% | 7.3% |
| 60Δ | 1.49 | 132.2% | 6.9% | |||
| 65Δ | 1.64 | 153.2% | 6.5% | |||
| 70Δ | 1.79 | 174.3% | 6.2% | |||
| 75Δ | 1.94 | 195.3% | 5.8% | |||
| 80Δ | 2.40 | 219.0% | 4.7% | |||
20Δ
- Pseudo strike
- 1.83
- IV
- 136.6%
- B/E move
- 84.8%
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- 1.71
- IV
- 125.2%
- B/E move
- 74.0%
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- 1.60
- IV
- 113.9%
- B/E move
- 63.1%
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- 1.48
- IV
- 102.5%
- B/E move
- 52.3%
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- 1.37
- IV
- 91.1%
- B/E move
- 41.5%
- Pseudo strike
- IV
- B/E move
45Δ
- Pseudo strike
- 1.25
- IV
- 79.7%
- B/E move
- 30.7%
- Pseudo strike
- 1.04
- IV
- 69.0%
- B/E move
- 8.0%
50Δ
- Pseudo strike
- 1.14
- IV
- 68.4%
- B/E move
- 19.9%
- Pseudo strike
- 1.19
- IV
- 90.0%
- B/E move
- 7.7%
55Δ
- Pseudo strike
- 1.02
- IV
- 57.0%
- B/E move
- 9.1%
- Pseudo strike
- 1.34
- IV
- 111.1%
- B/E move
- 7.3%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.49
- IV
- 132.2%
- B/E move
- 6.9%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.64
- IV
- 153.2%
- B/E move
- 6.5%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.79
- IV
- 174.3%
- B/E move
- 6.2%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 1.94
- IV
- 195.3%
- B/E move
- 5.8%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.40
- IV
- 219.0%
- B/E move
- 4.7%
Options history
Table
| Date | IV (%) |
|---|---|
| 105.73% |
Biotechnology
GHRS
GH Research PLC is a pioneering clinical-stage biopharmaceutical company focused on developing psilocybin-based therapies for psychiatric and neurodegenerative disorders. The…
More →GLUE
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new precision small molecule drugs that employ the body's natural mechanisms to selectively…
More →GMAB
Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark.
More →GNLX
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive…
More →GPCR
Description unavailable
More →GRCE
Description unavailable
More →